Key Clinical Summary: From Ideal to Real: Making Guideline-Based Treatment Decisions for Bladder Cancer in Every Care Setting

This is a micro-learning module summary of a presentation by Dr. Petros Grivas and Dr. Benjamin Garmezy which you can find here. Before participating, please read our CME and disclosure information which can be found here.

This program is supported by an independent education grant from MSD. This online education program has been designed solely for healthcare professionals in the US. The content is not intended for healthcare professionals in any other country.

1. Interpreting Diagnostic and Prognostic Factors for Risk Assessment/Stratification

Accurate risk stratification in bladder cancer begins with high-quality pathology, complete clinical staging, and recognition/analysis of key clinical risk factors.

In non-muscle invasive bladder cancer (NMIBC), high-risk disease typically includes high-grade tumors, clinical stage Ta or T1 (papillary tumors) and/or carcinoma in situ (CIS); other features that should be assessed include lymphovascular invasion, histology subtype/variant, multifocal tumors, tumor size/burden and location, urinary symptoms, bladder function, and recurrence (and timing of) after prior intravesical therapy, among others. Such features are associated with the risk of cancer recurrence and progression.

A complete and high-quality TURBT per guidelines is essential for accurate clinical staging. Presence of muscularis propria in the specimen is critical, as absence increases further the risk of under-staging and inappropriate treatment selection. Pathology reports should clearly document tumor grade/stage, depth of invasion, histologic subtype presence or absence, whether there is CIS and/or lymphovascular invasion.

For muscle-invasive bladder cancer (MIBC) and advanced/metastatic disease, clinical staging should include cross-sectional imaging of chest, abdomen, pelvis to evaluate local extent and metastatic spread, while there can be specific clinical scenarios that may be informed by the selective use of MRI abdomen/pelvis, bone scan or PET-CT. Imaging findings help guide treatment intent (curative vs palliative), determine tumor resectability, and inform referral decisions to specialty and multi-disciplinary care.

Clinical risk assessment should also incorporate patient-specific factors, including, but not limited to, performance status, organ function, medical comorbidities, frailty, nutrition, social/family support, and access to specialty care, particularly in community and rural settings, where resource availability may significantly influence management options.

2. Applying Diagnostic Findings to Guide Escalation, Referral, and Treatment Planning

Diagnostic findings should prompt timely escalation when disease complexity exceeds local resources/expertise and/or when findings suggest high-risk biology. Repeat TURBT or referral to specialized centers should be considered in general and especially when initial resection is incomplete, muscularis propria is absent, pathology is unclear, or if high-risk features, such as T1/Ta high-grade tumor, CIS, or histology subtype, etc. are identified.

Referral for multidisciplinary evaluation is important and overall recommended, especially in examples listed below:

High-risk NMIBC, esp. with toxicity, recurrence or BCG-unresponsive status
Newly diagnosed MIBC
Locally advanced or metastatic disease
Patients requiring complex systemic therapy, radiation or cystectomy evaluation

Escalation is also necessary when treatment-related toxicities exceed local management capabilities. Clear protocols for optimal symptom monitoring, recognition and referral can help identify complications early and reduce potential treatment delays.

Care decisions should balance disease management urgency with available local resources, using referral pathways and shared-care models when specialty services are not immediately accessible. Emphasis on assessment for genetic germline testing necessity (based on several factors) and referral for clinical trials should also be placed.

3. Implementing Guideline-Aligned Treatment Pathways

Management should follow evidence-based pathways while remaining adaptable to local operational workflows and access constraints.

High-Risk NMIBC

Standard management includes complete TURBT followed by intravesical therapy, most commonly BCG (if available). Patients with persistent or recurrent high-risk disease after adequate BCG require reassessment and consideration of alternative bladder-preserving therapies or radical cystectomy based on a detailed balanced discussion of pros/cons. Treatment selection depends on recurrence pattern and timing, whether adequate BCG course was given, patient fitness, symptoms, quality of life and preferences, potential bladder preservation goals, and treatment availability, among several other factors.

Muscle-Invasive Bladder Cancer (MIBC)

Curative-intent management typically includes neoadjuvant systemic therapy followed by radical cystectomy and lymph node dissection followed by likely adjuvant systemic therapy in fit patients who can tolerate it. Perioperative systemic approaches continue to evolve and should be integrated into practice as appropriate per guidelines.
Bladder-preserving strategies may be appropriate for selected patients who either are medically inoperable or decline radical cystectomy; these strategies should be discussed in the context of multi-disciplinary care as supported by guidelines. Early multi/inter-disciplinary coordination among urology, medical oncology, radiation oncology, radiology, and pathology improves treatment selection and outcomes.

Metastatic Disease

First-line systemic therapy selection depends on performance status, organ function, medical comorbidities, frailty, nutritional, social/family support, treatment eligibility, prior therapies, among other factors.
Overall treatment planning should incorporate:

Platinum (cisplatin and carboplatin) eligibility (although enfortumab-vedotin + pembrolizumab is the clearly preferred standard of care in the frontline setting)
Molecular profiling / biomarkers, e.g. tumor next generation sequencing for somatic testing including FGFR3 susceptible alterations, HER2 IHC (gastric scoring)
Prior exposure to systemic therapy, e.g. which regimen, timing of recurrence
Expected toxicity burden, drug interactions assessment, quality of life
Access to infusion center, multi-disciplinary and specialty support

Biomarker-directed treatment options are increasingly important in the second and later-line settings and should be integrated into routine care planning from the time of diagnosis of advanced/metastatic disease.

4. Navigating Resource Limitations and Strengthening Care Coordination

Consistent optimal bladder cancer management requires proactive strategies to address care delivery barriers, especially in underserved, community and rural practice settings.

Common barriers include:

Limited access to specialist/expert care, tumor somatic and germline genetic testing, nutritionist, etc.
Delayed lab, imaging and/or pathology review
Fragmented communication across care teams, lack of multi-disciplinary care
Geographic travel burden/distance from cancer center
Financial barriers/toxicity from diagnostic tests and treatment

Practical strategies to improve care coordination include:

Establishing clear referral pathways for high-risk or complex cases
Using multidisciplinary tumor boards for treatment planning
Standardizing optimal communication and collaboration between urology, oncology, pathology, radiology, etc.
Expanding telehealth and virtual follow-up when appropriate and feasible
Engaging advance practice providers, nurse navigators, pharmacists to support treatment adherence/compliance and close toxicity monitoring

Improved care coordination reduces delay in diagnosis, accelerates proper treatment initiation, and supports more consistent delivery of evidence-based and guideline-aligned care across diverse practice settings.

Clinical Takeaway

Effective bladder cancer management depends on accurate staging, early recognition of high-risk disease, timely escalation to specialty care, and coordinated multidisciplinary treatment planning. In resource-limited settings, structured workflows and strong referral networks are essential to ensure patients receive timely, guideline-aligned care across the disease continuum aiming to optimize clinical outcomes.

Content is accurate as of the date of release on 3 July 2026.